Aethlon medical announces contracting with ppd to advance hemopurifier clinical programs

San diego, sept. 30,  2021 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with ppd, inc. (nasdaq: ppd), a leading global contract research organization (cro), for ppd to oversee the company's clinical studies investigating the hemopurifier, aethlon's therapeutic blood filtration system, for infectious disease indications.
AEMD Ratings Summary
AEMD Quant Ranking